Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 4 3Phase 3 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Hutchinson's Melanotic Freckle 1Bowen's Disease 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Imiquimod × Clear all
NCT01088737 2019-08-13

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Medical University of Graz

Phase 2/3 Unknown
60 enrolled
Dermatologic

Melanoma, Hutchinson's Melanotic Freckle

NCT00384124 2008-03-26

Topical Imiquimod for Bowen's Disease of the Head and Neck

Brooke Army Medical Center

Phase 2/3 Unknown
50 enrolled

Bowen's Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡